The Lancet Infectious Diseases in conversation with
The Lancet Group
18 episodes
2 weeks ago
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
All content for The Lancet Infectious Diseases in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
The Lancet Infectious Diseases in conversation with
18 minutes
1 year ago
Prasad Kulkarni on dengue monoclonal antibodies
Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.Read the full article:https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninfContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://insta...
The Lancet Infectious Diseases in conversation with
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
